Concepedia

Marja Mergui‐Roelvink

MM

Statistics

Publications

23

Citations

5.3K

H-Index

18

Active since

2009

Affiliations

The Netherlands Cancer Institute(Current)

Utrecht University

Oncode Institute

University Medical Center Utrecht

Slotervaartziekenhuis

Marja Mergui‐Roelvink is an author at The Netherlands Cancer Institute specializing in pharmacology, cancer pharmacology, and medicine.

Publications per year

2009–2020

23

Publications

23

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · New England Journal of Medicine · 2009 · 3.6K citations · Full text

, , +17

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in <i>BRCA</i> Carrier Ovarian Cancer Correlating With Platinum-Free Interval

Peter C.C. Fong, Timothy A. Yap, David S. Boss et al. · Journal of Clinical Oncology · 2010 · 992 citations · Full text

, , +17

The Effect of St John’s Wort on the Pharmacokinetics of Docetaxel

Andrew K.L. Goey, Irma Meijerman, Hilde Rosing et al. · Clinical Pharmacokinetics · 2013 · 66 citations

, , +5

Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomas

Anne-Charlotte Dubbelman, Hilde Rosing, Cynthia M. Nijenhuis et al. · Investigational New Drugs · 2014 · 60 citations · Full text

, , +9

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment

Lot A. Devriese, Petronella O. Witteveen, Silvia Marchetti et al. · Cancer Chemotherapy and Pharmacology · 2012 · 50 citations

, , +16

1–5 of 23